Molecular Basis for the Immunostimulatory Potency of Small Interfering RNAs by Sioud, Mouldy & Furset, Gro
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2006, Article ID 23429, Pages 1–4
DOI 10.1155/JBB/2006/23429
ReviewArticle
Molecular Basis for the Immunostimulatory
Potency of Small Interfering RNAs
Mouldy Sioud and Gro Furset
Department of Immunology, Molecular Medicine Group, Institute for Cancer Research, Montebello, 0310 Oslo, Norway
Received 5 March 2006; Revised 15 June 2006; Accepted 28 June 2006
Small interfering RNAs (siRNAs) represent a new class of antigene agents, which has emerged as a powerful tool for functional
genomics and might serve as a potent therapeutic approach. However, several studies have showed that they could trigger several
bystander eﬀects,includingimmuneactivationandinhibitionofunintendedtargetgenes.Althoughactivationofinnateimmunity
by siRNAs might be beneﬁcial for therapy in some instances, uncontrolled activation can be toxic, and is therefore a major chal-
lenging problem. Interestingly, replacement of uridines in siRNA sequences with their 2-modiﬁed counterparts abrogated siRNA
bystander eﬀects. Here we highlight these important ﬁndings that are expected to facilitate the rational design of siRNAs that avoid
the induction of bystander eﬀects.
Copyright © 2006 M. Sioud and G. Furset. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
A variety of well-documented approaches have been de-
veloped for inhibiting gene expression. These include the
use of antisense RNAs, oligodeoxynucleotides (ODNs), ri-
bozymes, and RNA interference (RNAi) [1–3]. Among these
approaches, RNAi-mediated mRNA degradation is emerg-
ing as the most highly eﬀective antigene strategies [2, 3]. Al-
though the same phenomenon was described in transgenic
plants in the late 1980s [4], only in 1998 Fire and colleagues
have demonstrated that ds RNA introduced into Caenorhab-
ditis elegans can silence the expression of homologous tar-
get gene by directing degradation of its mRNA [5]. During
RNAi, the precursor double-stranded (ds) RNA is processed
by the Dicer endonuclease into short 21–24 nucleotides ds
siRNAs containing 2-base 3-overhangs. Subsequently, the
siRNA duplexes are then incorporated into a multiprotein
complex, the RNA-induced silencing complex (RISC), which
mediates the degradation of mRNAs with sequence homol-
ogous to the siRNA. Recent studies have showed that nu-
cleotides 2–8 of the siRNA antisense strand form a seed se-
quence that directs target mRNA recognition [6]. Some of
the protein components of RISC have been identiﬁed and as-
signedfunctions.Argonaute2(Ago2)istheRNAendonucle-
ase that cleaves target mRNA [7].
Despite the demonstration of RNAi in plants and worms,
researchers have been pessimistic about using RNAi in
mammalian cells due to the induction of the interferon
(INF) pathway by long ds RNAs (> 30 nucleotides), leading
to nonspeciﬁc inhibition of protein synthesis and degrada-
tion of mRNAs [8]. However, Tuschl and colleagues found
that siRNA duplexes mimicking the siRNAs generated by
Dicer cleavage in lower organisms could trigger RNAi with-
out inducing the IFN pathway, which is observed with long
double-stranded RNA in most cell types [9]. This discovery
has paved the way for the study of gene function in mam-
malian cells. In contrast to invertebrates, mammalian cells
do not have transitive RNAi because of the absence of RNA-
dependent RNA polymerase [2, 3]. Consequently, the num-
ber of siRNA molecules introduced into a cell limits gene
silencing induced by synthetic siRNAs. To circumvent this
potential problem, several groups have developed expression
vectors that direct the synthesis of RNA duplexes or short
hairpin RNAs (shRNAs) in mammalian cells, leading to sus-
tained production of siRNAs [3]. One approach for silencing
relies on the expression of shRNAs under the control of H1
or U6 pol III promoter, which is active in most mammalian
cell types.
During the last 5 years, siRNA-mediated gene knock-
downhasbecomeastandardmethodforstudyinggenefunc-
tion and drug target validation. However, despite the success
thathasbeenachieved,someseriousconcernssuchastheac-
tivation of innate immunity, inhibition of unintended target
mRNAs,andpotentialinterferencewithregulatoryfunctions2 Journal of Biomedicine and Biotechnology
of endogenous microRNAs need to be resolved prior thera-
peutic applications in humans [2, 10–12].
CELLULAR RESPONSE TO siRNAs
The gradual maturation of RNAi technology from the labo-
ratory to the clinic involves several major challenges, many
of which still need to be resolved. These include delivery to
target cells, intracellular stability, and speciﬁcity [2, 3]. It
should be noted that the introduction of synthetic siRNAs
into mammalian cells in culture is relatively simple by trans-
fection reagents [9]. siRNAs can be chemically synthesized,
or produced by in vitro transcription or by digestion of long
dsRNAs by recombinant RNase III or Dicer [2, 3]. Most of
the techniques that have been used for antisense delivery can
be applied to synthetic siRNAs and to DNA constructs en-
gineered to express shRNAs. These include electroporation,
cell microinjection, and lipophilic transfection [13].
Although siRNAs were initially thought to be small
enough to avoid the activation of the IFN pathway [9], re-
cent studies showed they could activate innate immunity in
mammalian cells [10, 14–16]. In this respect, Sledz and col-
leagues reported that siRNA could activate PKR, and the ef-
fects were sequence independent and do not occur with the
sense or the antisense RNA used to prepare the siRNA du-
plexes [15]. In contrast, Kariko and colleagues found that
siRNA could activate cytokine and interferon production via
TLR3, a receptor known to bind viral ds RNAs [16]. TLR3 is
mainly expressed on the cell surface. However, we and oth-
ers recently have demonstrated that PKR and TLR-3 do not
represent the major mechanism by which chemically syn-
thesized siRNA activate innate immunity [17–19]. In addi-
tion, internalization of ds siRNAs or ss siRNAs is required
forimmuneactivation.Indeed,inhibitorsofendosomalmat-
uration/acidiﬁcation like baﬁlomycin A1, a drug that inhibit
endosomal H+-proton pumps, blocked immune activation
[17], indicating the involvement of endosomal TLR7 and
TLR8. Consistent with the role of endosomal TLRs in siRNA
signaling, TLR7 knockout mice did not mount immune acti-
vation in response to siRNAs [18]. Taken together, the avail-
able data indicate that immune cells such as monocytes and
dendritic cells recognize ds siRNAs and ss siRNAs through
TLR7 and TLR8, leading to the production of inﬂammatory
cytokines and type I interferons [20]. We also found that ss
siRNAs are more eﬀective than ds siRNA in triggering TLR7
and TLR8 responses [17, 21]. In addition, we have found
that human bone marrow hematopoietic CD34+ progeni-
tor cells express TLR7 and TLR8. Interestingly, incubation of
these cells with either immunostimulatory synthetic siRNAs
or R848, a speciﬁc ligand for TLR7 and TLR8, induced their
diﬀerentiation into the myeloid lineage (Sioud et al in prepa-
ration).Thus,theinteractionofviralRNAswithCD34+pro-
genitor cells may increase the pool of innate immune cells.
As mentioned above mammalian cells respond to siR-
NAs, provided they are delivered to the endosomes. Notably,
the immune system uses a set of germ line encoded recep-
tors called pattern recognition receptors (PRRs) to recognize
common microbial structures known as pathogen associated
molecular patterns [22]. Whereas several TLRs are expressed
in the cell surface, TLR3, TLR7, TLR8, and TLR9, traﬃcb e -
tween the endoplasmic reticulum and intracellular compart-
ment such as the endosomes and the lysosomes [22]. An ob-
vious function of these traﬃcking pathways is to scan for
viral and/or bacterial nucleic acids, thus playing a central
role in innate antiviral responses. Therefore siRNAs inter-
nalized via endocytosis are more likely to activate endoso-
mal TLRs. It should be noted that cytoplasmic delivery of
immunostimulatoty synthetic siRNAs or shRNA did not in-
duce immune response in human blood cells [17, 21], sug-
gesting that they are not recognized by cytolasmic sensors of
ds RNAs. In this respect, a recent study has showed that en-
dogenously expressed shRNAs are not immunostimulatory
in human cells [23]. Interestingly, Williams and colleagues
demonstrated that the presence of 2-base 3-overhangs in
synthetic siRNAs or in Dicer processed shRNAs blocks the
activation of RIG-1, a major cytolasmic sensor for viral ds
RNAs [24].
STRUCTURE FEATURES THAT ACTIVATED
TLR7 AND TLR8
Initial experiments indicate that some types of secondary
structures and/or speciﬁc nucleotides are responsible for the
activationofNF-κBsignalingpathwaybysiRNAsinadherent
PBMC, an enriched monocyte population [10]. Monocytes
are circulating peripheral blood cells that can be diﬀerenti-
ated by cytokines into macrophages of diﬀerent phenotypes
as well as into dendritic cells. As mentioned above, siRNA ef-
fects are sequence dependent and can occur with ds siRNAs
andsssiRNAs[20].Thus,whatisthenatureofIFN-inducing
motif present in one sequence but absent in another? Al-
though GU dinucleotides were found to trigger TLR7 and
TLR8 activation [25], their absolute requirement in siRNA
activation of innate immunity is still not clear [21]. Judge
and colleagues identiﬁed one RNA motif and its immunos-
timulatory eﬀect seems to depend on the GU content [19].
However, Hornung and colleagues identiﬁed a second RNA
motif that is recognized by TLR7 in the context of siRNA du-
plexes and the activity does not depend on GU content [18].
It is worth noting that several siRNA sequences without GU
nucleotides activated the immune system [21, 26]. Thus, it is
likely that in addition to GU dinucleotides other characteris-
tics such as RNA structure, base position, and base composi-
tion of the siRNA ﬂanking sequences may be involved.
2’-RIBOSE MODIFICATIONS OF URIDINES
BLOCKS IMMUNE ACTIVATION
The identiﬁcation of the immunostimulatory sequence that
can activate innate immunity will allow the design of siRNAs
to minimize activation or to increase the immune response
for combating infections and tumor cells. Considering the
simplicity of the immunostimulatory motifs and their high
frequency in human RNAs, it is desirable to ﬁnd strategies
that evade immune recognition of siRNAs. At least two ba-
sic strategies can be used to block immune recognition ofM. Sioud and G. Furset 3
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Figure 1: Unmodiﬁed siRNA duplexes and single-stranded siR-
NAs (sense or antisense strand) activate innate immunity through
TLR7andTLR8resultingincytokinesandtypeIinterferonproduc-
tion. 2-ribose modiﬁcations of uridines abrogate TLR recognition
of RNAs and therefore signaling [21]. Modiﬁed ss siRNAs did not
compete with unmodiﬁed siRNAs to activate TLR signaling, indi-
cating that 2 modiﬁcations of uridines block the binding to TLRs
(unpublished data).
siRNA. One is to use delivery agents that avoid the delivery
and/or retention of siRNA within the endosomes. The other
is to apply chemical modiﬁcations. Regarding the ﬁrst strat-
egy, Song and colleagues described an antibody-based de-
livery strategy that can result in gene silencing without im-
mune activation [27]. The second strategy relies in the use
of modiﬁed nucleotides, which are essential to protect siR-
NAs from nuclease degradation and ameliorate their phar-
macokinetic parameters in vivo [13]. However, the chemical
modiﬁcation that blocks immune activation must be chosen
carefully so as not to inhibit siRNA silencing activity. Thus,
ﬁnding the appropriate chemical modiﬁcations for inhibit-
ing siRNA immune activation will be important for explor-
ing their therapeutic applications. In this respect, replace-
ment of the 2-hydroxyl uridines with either 2-ﬂuoro, 2-
deoxy, or 2-O-methyl uridines abrogated immune recogni-
tion of siRNAs by TLRs [21]. Thus, endosomal TLRs can dis-
tinguishbetweenmodiﬁedandunmodiﬁedRNAs(Figure 1).
In order to distinguish between self and nonself RNAs, the
immunesystemmayusebothendosomalcompartmentaliza-
tionandRNAmodiﬁcationstrategies[20].Collectively,these
recent ﬁndings oﬀer the possibility of choosing the appropri-
ate modiﬁcations that evade immune activation without re-
ducing siRNA-silencing potency. Of note, siRNA with either
2-ﬂuoro uridines or 2-deoxy uridines maintained silencing
activity [26, 28].
Another potential source of toxicity is the destruction of
cellular mRNAs that share partial homology to the siRNA se-
quences. Indeed, recent studies demonstrated that both siR-
NAs and microRNAs could interact with undesired target
mRNAs via base pairing of only few nucleotides, leading to
inhibition of gene expression [12, 29]. Interestingly, we have
found that chemical modiﬁcations of siRNAs not only evade
immune activation but also reduce the ss siRNAs and ds
siRNA “oﬀ-target eﬀects” [30]. Although the evading mech-
anism is not known, it is probable that the interaction of ss
siRNAs or ds siRNAs with unintended cellular mRNAs is af-
fected by chemical modiﬁcations.
IMMUNOSTIMULATORY siRNAs AS
VACCINE ADJUVANTS
It is generally accepted that initiation of a speciﬁc im-
mune response requires activation of innate immunity re-
sulting in a proinﬂammatory response. The produced cy-
tokines and chemokines assist in activating and directing
the adaptive immune responses. Therefore, a vaccine has
to induce a proinﬂammatory response to be eﬀective. As
discussed above, siRNA sequences containing immunos-
timulatory motifs induced interferons, chemokines, pro-
inﬂammatory cytokines, monocyte diﬀerentiation, and den-
dritic cell maturation [20]. Activated DCs produce high lev-
els of IL-12, INF-α, and proinﬂammatory cytokines such as
IL-6 and TNF-α.I F N - α triggers not only innate immune
defense such as the activation of NK cells, but also adap-
tive Th-1 responses, which are important for killing tumor
cells and virus infected cells [20]. Engagement of endoso-
mal TLR7 and/or TLR8 with siRNAs causes activation of
at least three key transcription factors, NF-κB, IFN regu-
latory factor (IRF)-3, and IRF-7, which are important im-
mune responses [30]. Previous studies have shown that the
activation of TLR9 can improve both cell-mediated and hu-
moral responses to antigens [31]. Notably, endosomal TLR9
recognize unmethylated 2-deoxyribo (cytidine-phosphate-
guanosine) CpG motifs that are more commonly found in
bacterial and viral genomes [32]. Most, but not all, CpG din-
ucleotidesaremethylatedinthegenomicDNAofvertebrates.
Although much remains to be revealed regarding the adju-
vant potency of RNA oligonucleotides, the reported data in-
dicate that ss siRNA- and ds siRNAs-containing immunos-
timulatory RNA motifs might improve cancer and viral vac-
cines.
CONCLUDING REMARKS
As with any new agent, issues of delivery and speciﬁcity
are major obstacles before siRNAs can be used in pa-
tients.Similartoantisenseoligonucleotides,certainsynthetic
siRNAs activated innate immunity via TLRs, in particu-
lar TLR7 and TLR8. Therefore, there is a need to examine4 Journal of Biomedicine and Biotechnology
the immunostimulatory eﬀects of any potential therapeu-
tic siRNA in human immune cells prior to clinical applica-
tions. The recent ﬁndings clearly show that the 2-hydroxyl
uridines are absolutely essential for TLR7 and/or TLR8
recognition and signaling. Indeed, replacement of uridines
with 2-ﬂuoro, 2-deoxy, or 2-O-methyl modiﬁed counter-
parts abrogated immune activation by ss siRNA and siRNA
duplexes. Alternatively, the presence of 2-modiﬁed uridines
might protect siRNAs for being sensed by the immune sys-
tem. Also, most of the other bystander eﬀects not related to
immune activation were also inhibited by chemical modiﬁ-
cations. These ﬁndings will enable the rational design of siR-
NAs that avoid the induction of bystander eﬀects.
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